|
U.S. Patent No. 6,759,236: |
Methods to enhance and confine expression of genes |
|
U.S. Patent No. 6,756,410: |
Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2 |
|
U.S. Patent No. 6,740,735: |
DNA encoding human apoB48R: a monocyte-macrophage apolipoprotein B48 receptor gene and protein |
|
U.S. Patent No. 6,734,337: |
Acetyl-coenzyme A carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action |
|
U.S. Patent No. 6,726,934: |
Micro-particulate and nano-particulate polymeric delivery system |
|
U.S. Patent No. 6,716,622: |
Tissue-specific self-inactivating gene therapy vector |
|
U.S. Patent No. 6,706,481: |
In vitro selection of signaling aptamers |
|
U.S. Patent No. 6,703,384: |
Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
|
U.S. Patent No. 6,703,375: |
Molecular chemotherapy enhancement of radiotherapy |
|
U.S. Patent No. 6,699,473: |
Human anti-epidermal growth factor receptor single-chain antibodies |
|
U.S. Patent No. 6,692,744: |
Betaglycan as an inhibin receptor and uses thereof |
|
U.S. Patent No. 6,689,380: |
Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy |
|
U.S. Patent No. 6,686,345: |
DNA-cleaving antitumor agents |
|
U.S. Patent No. 6,686,200: |
Methods and compositions for the large scale production of recombinant adeno-associated virus |
|
U.S. Patent No. 6,683,170: |
Ligands added to adenovirus fiber |
|
U.S. Patent No. 6,683,162: |
Targeted alpha particle therapy using actinium-255 conjugates |
|
U.S. Patent No. 6,677,444: |
Melanoma antigens and methods of use |
|
U.S. Patent No. 6,673,214: |
Energy enhanced reaction catalysis and uses thereof |
|
U.S. Patent No. 6,669,938: |
ImmunoConjucates for cancer diagnosis and therapy |
|
U.S. Patent No. 6,669,937: |
Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
|
U.S. Patent No. 6,664,394: |
Derivatives of butyric acid |
|
U.S. Patent No. 6,660,741: |
Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor |
|
U.S. Patent No. 6,660,269: |
Homologous 28-kilodalton immunodominant protein genes of Ehrlichia canis and uses thereof |
|
U.S. Patent No. 6,656,916: |
Glucocorticoid enhancement of gene expression |
|
U.S. Patent No. 6,656,490: |
Opthalmologic uses of protein C |
|
U.S. Patent No. 6,649,741: |
TADG-15: an extracellular serine protease overexpressed in carcinomas |
|
U.S. Patent No. 6,649,637: |
Inhibition of intracellular replication by pyridinylimidazoles |
|
U.S. Patent No. 6,649,396: |
Fiber receptor-independent system for the propagation of adenoviral vectors |
|
U.S. Patent No. 6,645,998: |
Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
|
U.S. Patent No. 6,627,403: |
Methods for the early diagnosis of ovarian cancer |
|
U.S. Patent No. 6,610,289: |
Mutated herpes simplex virus type 1 thymidine kinases and uses thereof |
|
U.S. Patent No. 6,605,278: |
Uses of trank, a novel secretory cytokine |
|
U.S. Patent No. 6,603,127: |
Bismuth-213 generator and uses thereof |
|
U.S. Patent No. 6,602,896: |
p38MAPK inhibitor and uses thereof |
|
U.S. Patent No. 6,602,851: |
SMDF and GGF neuregulin splice variant isoforms and uses thereof |
|
U.S. Patent No. 6,602,674: |
Uses of antileukoprotease in carcinoma |
|
U.S. Patent No. 6,599,909: |
Molecular chemotherapy enhancement of radiotherapy |
|
U.S. Patent No. 6,599,505: |
Immunotoxins directed against CD33 related surface antigens |
|
U.S. Patent No. 6,596,529: |
Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
|
U.S. Patent No. 6,593,462: |
Purified .beta.1,2-xylosyltransferase and uses thereof |
|
U.S. Patent No. 6,590,393: |
High frequency large volume resonator |
|
U.S. Patent No. 6,589,995: |
Method of inhibiting pancreatic .beta.-cell p135 O-glycosylation |
|
U.S. Patent No. 6,589,533: |
Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
|
U.S. Patent No. 6,586,389: |
Cubilin protein, DNA sequences encoding cubilin and uses thereof |
|
U.S. Patent No. 6,576,618: |
Methods to enhance wound healing and enhanced wound coverage material |
|
U.S. Patent No. 6,573,491: |
Electromagnetic energy driven separation methods |
|
U.S. Patent No. 6,566,402: |
Use of citrate-containing dialysate for renal dialysis treatment |
|
U.S. Patent No. 6,566,333: |
Osteoclast secreted chemokine and uses thereof |
|
U.S. Patent No. 6,562,969: |
Ricin inhibitors and methods for use thereof |
|
U.S. Patent No. 6,555,368: |
Capsid-modified recombinant adenovirus and methods of use |
|
U.S. Patent No. 6,552,005: |
Molecular chemotherapy enhancement of radiotherapy |
|
U.S. Patent No. 6,548,738: |
ACC2-knockout mice and uses thereof |
|
U.S. Patent No. 6,546,278: |
Gated functional muscle imaging |
|
U.S. Patent No. 6,540,976: |
Method for reducing radiation toxicity |
|
U.S. Patent No. 6,532,387: |
Catheter for delivering electromagnetic energy for enhanced permeation of substances |
|
U.S. Patent No. 6,526,306: |
Intravaginal radiofrequency imaging device |
|
U.S. Patent No. 6,521,739: |
Complete genome sequence of a simian immunodeficiency virus from a red-capped mangabey |
|
U.S. Patent No. 6,518,028: |
Methods for the early diagnosis of ovarian and prostate cancer |
|
U.S. Patent No. 6,514,757: |
Nodavirus-like DNA expression vector and uses thereof |
|
U.S. Patent No. 6,503,540: |
Cloning and characterization of bves, a novel gene expressed in heart and uses thereof |
|
U.S. Patent No. 6,492,634: |
Optical monitor for sudden infant death syndrome |
|
U.S. Patent No. 6,492,110: |
Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1 |
|
U.S. Patent No. 6,475,986: |
Uses of THANK, a TNF homologue that activates apoptosis |
|
U.S. Patent No. 6,472,150: |
Sifter screening to identify biologically active molecules |
|
U.S. Patent No. 6,468,593: |
Plated non-conductive products and plating method for the same |
|
U.S. Patent No. 6,468,547: |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies |
|
U.S. Patent No. 6,461,844: |
Liver GalNAc-1-phosphate kinase |
|
U.S. Patent No. 6,458,942: |
28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof |
|
U.S. Patent No. 6,451,583: |
Pharmacological targeting of mRNA cap formation for treatment of parasitic infections |
|
U.S. Patent No. 6,451,570: |
Mutants of monoamine oxidase B |
|
U.S. Patent No. 6,448,033: |
Method of synthesizing a fluorescently labeled protein |
|
U.S. Patent No. 6,448,014: |
PCR-hybridization assays specific for integrated retroviruses |
|
U.S. Patent No. 6,440,714: |
Tyr393 and Tyr398 mutants of monoamine oxidase B |
|
U.S. Patent No. 6,440,393: |
Carbon dioxide enhancement of inhalation therapy |
|
U.S. Patent No. 6,436,393: |
Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof |
|
U.S. Patent No. 6,424,863: |
Delivery of pharmaceutical compounds and collection of biomolecules using electromagnetic energy and uses thereof |
|
U.S. Patent No. 6,420,163: |
Pharmacological targeting of mRNA cap formation |
|
U.S. Patent No. 6,419,919: |
Method for the augmentation of gene expression |
|
U.S. Patent No. 6,417,223: |
Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof |
|
U.S. Patent No. 6,416,987: |
Mutants of thymidylate synthase and uses thereof |
|
U.S. Patent No. 6,407,107: |
Derivatives of butyric acid and uses thereof |
|
U.S. Patent No. 6,403,780: |
Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
|
U.S. Patent No. 6,392,023: |
Homologous 28-kilodalton immunodominant protein genes of Ehrlicha canis and uses thereof |
|
U.S. Patent No. 6,389,313: |
Laser probes for drug permeation |
|
U.S. Patent No. 6,383,794: |
Methods of producing high titer recombinant adeno-associated virus |
|
U.S. Patent No. 6,383,478: |
Polymeric encapsulation system promoting angiogenesis |
|
U.S. Patent No. 6,376,218: |
Expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof |
|
U.S. Patent No. 6,376,171: |
Methods of screening for antiviral compounds |
|
U.S. Patent No. 6,375,980: |
Stabilization of lipid:DNA formulations during nebulizatio |
|
U.S. Patent No. 6,372,727: |
Metalloporphyrin treatment of neurologic disease |
|
U.S. Patent No. 6,372,435: |
Methods of surveying for CC (Beta) chemokine receptor variants and their association with HIV-1 transmission and/or dis ease progression |
|
U.S. Patent No. 6,368,790: |
cDNA encoding P2P proteins and use of P2P cDNA derived antibodies and antisense reagents in determining the proliferative potential of normal, abnormal, and cancer cells in animals and humans |
|
U.S. Patent No. 6,361,995: |
Protection of pancreatic .beta.-cells during islet isolation and assessment of islet viability and candidate diabetes drugs after islet isolation |
|
U.S. Patent No. 6,355,777: |
P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof |
|
U.S. Patent No. 6,353,753: |
Optical imaging of deep anatomic structures |
|
U.S. Patent No. 6,353,152: |
Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
|
U.S. Patent No. 6,352,723: |
Brain-derived alkali-soluble immunoregulatory composition |
|
U.S. Patent No. 6,352,517: |
Optical monitor of anatomical movement and uses thereof |
|
U.S. Patent No. 6,346,243: |
Inhibition of transplant rejection by type one interferon |
|
U.S. Patent No. 6,346,233: |
Composition for treating cancer via liposomal aerosol formulation containing taxol |
|
U.S. Patent No. 6,344,324: |
Quantification of cellular injury using expression of a fluorescent protein under the control of the GADD153 promoter |
|
U.S. Patent No. 6,334,999: |
Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs |
|
U.S. Patent No. 6,333,030: |
Chimeric retrovirus/adenovirus system |
|
U.S. Patent No. 6,329,153: |
Method for evaluating immunosuppressive regimens
|
|
U.S. Patent No. 6,322,974: |
Mitochondrial DNA damage as a predictor of coronary atherosclerotic heart disease |
|
U.S. Patent No. 6,320,027: |
Nucleotide sequence of the nucleocapsid gene of oropouche virus |
|
U.S. Patent No. 6,316,213: |
Methods for the early diagnosis of ovarian, breast and lung cancer |
|
U.S. Patent No. 6,312,699: |
Ligands added to adenovirus fiber |
|
U.S. Patent No. 6,309,839: |
Screening methods for compounds that inhibit or stimulate helicase enzyme activity |
|
U.S. Patent No. 6,306,626: |
Anti-IgM monoclonal antibodies and methods of their use |
|
U.S. Patent No. 6,303,318: |
Methods for the early diagnosis of ovarian cancer |
|
U.S. Patent No. 6,303,307: |
Large scale genotyping of disease and a diagnostic test for spinocerebellar ataxia type 6 |
|
U.S. Patent No. 6,297,284: |
DNA-cleaving antitumor agents |
|
U.S. Patent No. 6,294,344: |
Methods for the early diagnosis of ovarian cancer |
|
U.S. Patent No. 6,291,663: |
TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma |
|
U.S. Patent No. 6,288,111: |
Combination cisplatin/tamoxifen therapy for human cancers |
|
U.S. Patent No. 6,287,775: |
Early detection of ovarian carcinoma using p16 gene products |
|
U.S. Patent No. 6,284,918: |
Selective inhibitors of prostaglandin endoperoxide synthase-2 |
|
U.S. Patent No. 6,284,742: |
Immunomodulation by genetic modification of dendritic cells and B cells |
|
U.S. Patent No. 6,284,508: |
Glucuronoxylomannan (GXM)-O-acetylhydrolase of Cryptococcus neoformans and uses thereof |
|
U.S. Patent No. 6,284,473: |
P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
|
U.S. Patent No. 6,284,464: |
Inhibition of binding of Hox and homeodomain-containing proteins and uses thereof |
|
U.S. Patent No. 6,281,014: |
SH3-containing protein, DNA and uses thereof |
|
U.S. Patent No. 6,268,165: |
Methods for the early diagnosis of ovarian cancer |
|
U.S. Patent No. 6,268,147: |
Nucleic acid analysis using sequence-targeted tandem hybridization |
|
|
|